AR087184A1 - Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen - Google Patents
Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR087184A1 AR087184A1 ARP120102550A ARP120102550A AR087184A1 AR 087184 A1 AR087184 A1 AR 087184A1 AR P120102550 A ARP120102550 A AR P120102550A AR P120102550 A ARP120102550 A AR P120102550A AR 087184 A1 AR087184 A1 AR 087184A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- group
- cycloalkyl
- alkyl
- heterocycle
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 1
- 208000035397 Ring chromosome 7 syndrome Diseases 0.000 abstract 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000532 dioxanyl group Chemical group 0.000 abstract 1
- 125000000597 dioxinyl group Chemical group 0.000 abstract 1
- 125000005879 dioxolanyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto que comprende la estructura de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: L es un enlazador que se selecciona a partir del grupo que consiste en un enlace directo, un alquileno C1-6 de cadena ramificada o recta, -SO2-, -C(O)NH-, y un resto de formula (2), en donde los grupos R9 y R10, junto con el átomo de carbono con el que están enlazados, pueden unirse opcionalmente entre sí para formar un cicloalquilo C3-7; R1 se selecciona a partir del alquilo C1-6 o cicloalquilo C3-7; R2 se selecciona a partir del grupo que consiste en -CO2R9, -C(O)R15 y los restos del grupo de formulas (3); R3 se selecciona a partir del grupo que consiste en alquilo C1-6, -OR10, R10(R14)q, tetrahidrofuranilo, oxetanilo, furanilo, dioxolanilo, piranilo, dioxanilo, dioxinilo, -O-cicloalquilo C3-7, y -cicloalquilo C3-7-(R10); R4 se selecciona a partir del grupo que consiste en arilo C5-15, cicloalquilo C3-7, heterociclo C2-9, y heteroarilo C2-9, en donde el heterociclo y el heteroarilo cada uno comprenden de uno a tres heteroátomos seleccionados a partir del S, N u O, y en donde cada grupo R4 está opcionalmente sustituido por uno a cuatro sustituyentes seleccionados a partir del R11; R5, R6, y R7 se seleccionan independientemente a partir del -H, alquilo C1-6, alcoxilo C1-6, halógeno, nitrilo, cicloalquilo C3-7, -OR10-arilo C5-15, -OR10R14, -OR10-arilo C5-15, -OR10-arilo C5-14-(R11)m, -OR9, -R10(Y)-(R12)n, -OR10R17, -R10R17, -R17R15, -OR10(R14)q, -OR10(Y), -OR10R18, -OSO2R15, -R15, -arilo C5-15, -(Y), -(Y)-(R12)n, -C(O)-(Y), -C(O)R15, -R10-arilo C5-15, -R10R15, y -arilo C5-14-R12, en donde R5 y R6, junto con los átomos de carbono con los que están enlazados, pueden unirse opcionalmente entre sí para formar un anillo de cicloalquilo C4-7, de heterociclo C2-9, o de arilo C5-15, o de una manera alternativa, cuando L es un enlace, R6 y R7, junto con los átomos de carbono con los que están enlazados, pueden unirse opcionalmente entre sí para formar un anillo de heterociclo C3-7 o de cicloalquilo C3-7; R9 se selecciona independientemente a partir del -H y alquilo C1-6; R10 es alquilo C1-6; R11, R12, y R13 se seleccionan independientemente a partir del grupo que consiste en alquilo C1-6, alcoxilo C1-6, butoxi-carbonilo, oxo, -R10OR10, halógeno, -R15, -R10(R14)q, -OR10(R14)q, -SO2R10 -C(O)R10, -C(O)R15, y -R10R17; R14 es halógeno; R15 es -N(R16)2; R16 se selecciona independientemente a partir del grupo que consiste en -H, alquilo C1-6, hidroxilo, -SO2R10, -SO2N(R10)2, -C(O)NHR10, -C(O)R18, y -arilo C5-14-(R11); R17 es -OR9; R18 es -CO2R9; Y se selecciona independientemente a partir del heterociclo C2-9 o heteroarilo C2-9, en donde cada uno tiene de uno a tres heteroátomos seleccionados a partir del S, N u O; m es cero o un entero seleccionado a partir del 1, 2, 3, ó 4; n es cero o un entero seleccionado a partir del 1, 2, ó 3; p es cero o un entero seleccionado a partir del 1, 2, ó 3; y q es un entero seleccionado a partir del 1, 2, ó 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508197P | 2011-07-15 | 2011-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087184A1 true AR087184A1 (es) | 2014-02-26 |
Family
ID=47519251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102550A AR087184A1 (es) | 2011-07-15 | 2012-07-13 | Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8609653B2 (es) |
| EP (1) | EP2731436B1 (es) |
| JP (1) | JP6055468B2 (es) |
| AR (1) | AR087184A1 (es) |
| ES (1) | ES2624984T3 (es) |
| TW (1) | TW201317237A (es) |
| UY (1) | UY34201A (es) |
| WO (1) | WO2013012649A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105330675A (zh) | 2010-11-15 | 2016-02-17 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
| CN104066732B (zh) | 2011-11-15 | 2016-04-13 | 韩国化学硏究院 | 新型抗病毒吡咯并吡啶衍生物及其制备方法 |
| PT2877468T (pt) * | 2012-07-12 | 2017-11-21 | Viiv Healthcare Uk Ltd | Compostos e métodos para o tratamento de vih |
| TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| US9944656B2 (en) | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US9834566B2 (en) | 2014-02-18 | 2017-12-05 | VIIV Healthcare UK (No.5) Limited | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3116879A1 (en) | 2014-02-18 | 2017-01-18 | VIIV Healthcare UK (No.5) Limited | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| CN103864661A (zh) * | 2014-04-01 | 2014-06-18 | 湖南华腾制药有限公司 | 一种2-氨基-3-氰基吡咯衍生物的合成工艺 |
| EP3144311A4 (en) | 2014-05-16 | 2018-01-03 | Shionogi & Co., Ltd. | Tricyclic heterocyclic derivative having hiv replication-inhibiting effect |
| KR101592370B1 (ko) * | 2014-06-09 | 2016-02-11 | 한국화학연구원 | 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도 |
| JP2017521428A (ja) * | 2014-07-08 | 2017-08-03 | ヴィーブ ヘルスケア ユーケー リミテッド | ウイルス感染症の治療に使用するためのイソインドリン誘導体 |
| TW201617315A (zh) | 2014-07-22 | 2016-05-16 | Ｖｉｉｖ醫療保健英國有限公司 | 異吲哚啉酮衍生物 |
| MX2017015256A (es) | 2015-05-29 | 2018-02-19 | Shionogi & Co | Derivados triciclicos que contienen nitrogeno que tienen actividad inhibidora de la replicacion del virus de inmunodeficiencia adquirida (vih). |
| BR112018000177A2 (pt) * | 2015-07-06 | 2018-09-04 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratar a infecção pelo hiv. |
| AU2016290151A1 (en) * | 2015-07-08 | 2018-01-18 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-YL acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| MY186368A (en) * | 2015-07-20 | 2021-07-16 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| JP2019522014A (ja) | 2016-07-25 | 2019-08-08 | ヴィーブ ヘルスケア ユーケー リミテッド | インドリン誘導体 |
| ES2938335T3 (es) * | 2017-03-24 | 2023-04-10 | St Pharm Co Ltd | Nuevo derivado de pirrolopiridina, método para producir el mismo y uso del mismo |
| TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| KR102909106B1 (ko) * | 2020-08-20 | 2026-01-07 | 에스티팜 주식회사 | 피롤로피리딘 유도체 및 이들의 용도 |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| JP7573115B2 (ja) * | 2021-01-11 | 2024-10-24 | エスティ ファーム カンパニー リミテッド | ピロロピリジン誘導体の製造方法 |
| CN113173884B (zh) * | 2021-05-06 | 2023-08-15 | 陕西师范大学 | 二氯二茂钛催化汉斯酯1,4-二氢吡啶类化合物合成吡啶及其衍生物的方法 |
| KR20240027782A (ko) * | 2021-12-02 | 2024-03-04 | 상하이 키젠트 파마슈티컬 컴퍼니 리미티드 | 방향족 화합물, 이의 약학 조성물 및 이의 용도 |
| WO2025159587A1 (ko) * | 2024-01-25 | 2025-07-31 | 에스티팜 주식회사 | 헤테로아릴 화합물 및 이의 용도 |
| WO2025159574A1 (ko) * | 2024-01-25 | 2025-07-31 | 에스티팜 주식회사 | 피롤로피리딘 화합물 및 이들의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP1196384A4 (en) * | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| CN1533390A (zh) | 2001-03-19 | 2004-09-29 | СҰҩƷ��ҵ��ʽ���� | 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物 |
| JP2008512380A (ja) * | 2004-09-03 | 2008-04-24 | プレキシコン，インコーポレーテッド | Ｐｄｅ４ｂ阻害剤 |
| WO2009062288A1 (en) * | 2007-11-15 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| WO2009062308A1 (en) * | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| BRPI0820307A2 (pt) | 2007-11-16 | 2019-09-24 | Boehringer Ingelheim Int | inibidores de replicação do vírus da imunodeficiência humana |
| EP2640705A2 (en) * | 2010-11-15 | 2013-09-25 | Katholieke Universiteit Leuven | Novel antiviral compounds |
-
2012
- 2012-07-12 ES ES12814906.9T patent/ES2624984T3/es active Active
- 2012-07-12 US US13/547,199 patent/US8609653B2/en not_active Expired - Fee Related
- 2012-07-12 JP JP2014520296A patent/JP6055468B2/ja not_active Expired - Fee Related
- 2012-07-12 EP EP12814906.9A patent/EP2731436B1/en active Active
- 2012-07-12 WO PCT/US2012/046354 patent/WO2013012649A1/en not_active Ceased
- 2012-07-13 UY UY0001034201A patent/UY34201A/es not_active Application Discontinuation
- 2012-07-13 TW TW101125458A patent/TW201317237A/zh unknown
- 2012-07-13 AR ARP120102550A patent/AR087184A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2731436A4 (en) | 2015-03-11 |
| TW201317237A (zh) | 2013-05-01 |
| ES2624984T3 (es) | 2017-07-18 |
| US8609653B2 (en) | 2013-12-17 |
| JP2014522858A (ja) | 2014-09-08 |
| UY34201A (es) | 2013-02-28 |
| JP6055468B2 (ja) | 2016-12-27 |
| WO2013012649A1 (en) | 2013-01-24 |
| EP2731436B1 (en) | 2017-03-08 |
| EP2731436A1 (en) | 2014-05-21 |
| US20130018049A1 (en) | 2013-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087184A1 (es) | Derivados de azaindol utiles para tratar infecciones por hiv y composiciones farmaceuticas que los contienen | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| ES2556350T3 (es) | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos | |
| AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR092838A1 (es) | COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4 | |
| AR082633A1 (es) | Analogos de tetraciclina | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR085893A1 (es) | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos | |
| AR087792A1 (es) | Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR086829A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR059901A1 (es) | Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |